Medical Oncology
  • Interests
  • Immunotherapy
  • Targeted Therapies
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancers
  • Gynecological Cancers
  • Urological Cancers
Medical Oncology
  • Interests
  • Immunotherapy
  • Targeted Therapies
  • Breast Cancer
  • Lung Cancer
  • Gastrointestinal Cancers
  • Gynecological Cancers
  • Urological Cancers
VM Medical Park Kocaeli (Başiskele)
Ovacık Mahallesi, Topsahası Sk. No:34, 41140 Başiskele/Kocaeli - Kocaeli

VM Medical Park Kocaeli (Başiskele)
Ovacık Mahallesi, Topsahası Sk. No:34, 41140 Başiskele/Kocaeli - Kocaeli

Academic Background

Education and Specializations
Hacettepe University Faculty of Medicine (1996-2003)
Kocaeli University Faculty of Medicine – Internal Medicine Residency (2003-2009)
Kartal Dr. Lütfi Kırdar Training and Research Hospital – Medical Oncology Residency (2010-2013)
Kartal Dr. Lütfi Kırdar Training and Research Hospital – Associate Professor (2017)
University of Health Sciences Faculty of Medicine – Faculty Member (2018-2023)
Experience
2003-2009: Kocaeli University Faculty of Medicine (Internal Medicine Residency)
2010-2013: Kartal Dr. Lütfi Kırdar Training and Research Hospital (Medical Oncology Residency)
2014-2017: Kartal Dr. Lütfi Kırdar Training and Research Hospital (Medical Oncology Specialist)
2017: Kartal Dr. Lütfi Kırdar Training and Research Hospital (Associate Professor)
2018-2023: University of Health Sciences Faculty of Medicine (Faculty Member)
2018-2023: Kocaeli Derince Training and Research Hospital - Medical Oncology and Internal Medicine Clinics (Training Coordinator)
2023-2023: Kocaeli City Hospital - Medical Oncology and Internal Medicine Clinics (Training Coordinator)
Professional Memberships

Member of the Turkish Medical Oncology Association
Member of the Oncology and Immunotherapy Association
Member of ESMO (European Society for Medical Oncology)
Member of ASCO (American Society of Clinical Oncology)
Member of Kocaeli Medical Chamber
Member of Istanbul Medical Chamber
Awards
10th Turkish Medical Oncology Congress, Antalya, 2023 (3rd Best Poster Award).
Aydin D, Kayır N: "Pathological Complete Response Rates in Gastric Cancer Patients Receiving Neoadjuvant FLOT Regimen."
7th Turkish Medical Oncology Congress, Antalya, 2018 (2nd Best Oral Presentation Award).
Aydin D, Şendur MA, Kefeli U: "Evaluation of the Efficacy of Bevacizumab in Advanced Small Bowel Adenocarcinoma."

Read more

Scientific Publications

1.Aydin D, Kefeli U, Ozcelik M, Erdem GU, Sendur MA, Yildirim ME, Oven BB, Bilici A, Gumus M.The Prognostic Utility of the Metastatic Lymph Node Ratio and the Number of Regional Lymph Nodes Removed from Patients with Small Bowel Adenocarcinomas. Medicina (Kaunas). 2023 Aug 16;59(8):1472. doi: 10.3390/medicina59081472.

2.Aydin D, Sendur MA, Kefeli U, Unal OU, Tastekin D, Akyol M, Tanrikulu E, Ciltas    A, Ustaalioglu BB, Uysal M, Esbag O, Yazilitas D, Tanrıverdi O, Bilici A, Arpaci E, Berk V, Yetisyigit T, Ozdemir NY, Oztop I, Alacacioglu A, Aydin O, Ozcelik M, Yildirim E, Dinc N, Gumus M. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection. Clin Colorectal Cancer 2017 Sep;16(3):220-227. doi: 10.1016/j.clcc.2016.08.002

Seker M, Aydin D, Bilici A, Yavuzer D, Ozgun MG, Ozcelik M, Aydin O, Aliustaoglu M. Correlation of Caveolin-1 Expression with Prognosis in Patients with Gastric Cancer after Gastrectomy. Oncol Res Treat 2017;40(4):185-190. doi: 10.1159/000456620

4.D Aydin, A Bilici, D Yavuzer, U Kefeli, A Tan, O Ercelep, A Mert, S Yuksel, M Ozcelik, D Isik, H Surmeli, H Odabasi, M Ustaalioglu Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin Transl Oncol 2015 Aug;17(8):604-11. doi: 10.1007/s12094-015-1283-1.

5.Erol C, Sakin A, Başoğlu T, Özden E, Çabuk D, Doğan M, Öksüzoğlu B, Yıldırım HÇ, Öner İ, Eryılmaz MK, Dülgar Ö, Aydın D, Doğan N, Özen M, Hacıbekiroğlu İ, Özdemir N, Gürler F, Paksoy N, Karabulut S, Aksoy A, Hızal M, Kahraman S, Şen E, Paydaş S, Çılbır E, Fırat F, Akdeniz N, Özçelik M, Oyman A, Baytemür NK, Acar R, Almuradova E, Karabulut B, Şakalar T, Arak H, Değerli E, Türker S, Alan Ö, Er Ö, Taşçı EŞ, Demir N, Çavdar E, Turhal S, Dede DŞ, Akıncı MB, Yalçın B, Yumuk F, Yalçın Ş, Şendur MAN. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group). Turk J Med Sci 2022 Aug;52(4):1022-1032. doi: 10.55730/1300-0144.5404.

6.D Aydin, A Bilici, S Kayahan, D Yavuzer, M Basar, M Ustaalioglu. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy. Clin Transl Oncol 2016 Jun;18(6):608-16. doi: 10.1007/s12094-015-1405-9.

7.Almuradova E, Basoglu T, Nayir E, Bayram E, Paydas S, Gokmen I, Karakaya S, Oksuzoglu B, Erdem D, Sakin A, Atcı M, Belen Gulbagcı B, Hacibekiroglu I, Onder AH, Karaarslan S, Karakurt Eryılmaz M, Korkmaz M, Yazıcı O, Sutcuoglu O, Akagunduz B, Arak H, Sakalar T, Aydin D, Iriagac Y, Alan O, Midik M, Cetin D, Kip AD, Turhal S, Kacan T, Koseci T. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study. Neoplasma 2023 Feb;70(1):158-165. doi: 10.4149/neo_2022_221004N984.

8.Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2016 Sep;27(5):408-414. doi: 10.5152/tjg.2016.15514

9.Yıldırım ME, Kefeli U, Aydın D, Sener N, Gümüş M. The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker. Tumour Biol 2016 Sep;37(9):11903-11907. doi: 10.1007/s13277-016-5025-y.

10.Aydin D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, Bilir C, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).
J BUON 2016 Sept-Oct;21(5):1242-1249

11.Ozcelik M, Korkmaz T, Odabas H, Gemici C, Ercelep O, Yuksel S, Mert AG, Surmeli H, Isik D, Aydin D, Seker M, Mayadagli A, Ozdemir P, Aliustaoglu M, Gumus M. Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients. Tumour Biol 2016 Jul;37(7):8901-7. doi: 10.1007/s13277-015-4776-1

12.Kefeli U, Yildirim ME, Aydin D, Madenci OC, Yasar N, Sener N, Mert AG, Yuksel S, Ercelep OB, Korkmaz T, Yildiz R, Gumus M. Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment. Biomarkers 2012 Nov;17(7):663-7. doi: 10.3109/1354750X.2012.709882.

13.Aydin D, Sendur MA, Kefeli U, Ustaalioglu BB, Aydin O, Yildirim E, Isik D, Ozcelik M, Surmeli H, Oyman A, Isik S, Sener N, Ercelep O, Odabas H, Aliustaoglu M, Gumus M. Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma. Clin Colorectal Cancer 2017 Mar;16(1):78-83. doi: 10.1016/j.clcc.2016.04.013.

14.Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC, Acar O, Aksoy S, Baytemur NK, Sahin E, Cabuk D, Basaran G, Paydas S, Yaren A, Guven DC, Erdogan AP, Demirci U, Yasar A, Bayoglu İV, Hizal M, Gulbagci B, Paksoy N, Davarci SE, Yilmaz F, Dogan O, Orhan SO, Kayikcioglu E, Aytac A, Keskinkilic M, Mocan EE, Unal OU, Aydin E, Yucel H, Isik D, Eren O, Uluc BO, Ozcelik M, Hacibekiroglu I, Aydiner A, Demir H, Oksuzoglu B, Cilbir E, Cubukcu E, Cetin B, Oktay E, Erol C, Okutur SK, Yildirim N, Alkan A, Selcukbiricik F, Aksoy A, Karakas Y, Ozkanli G, Duman BB, Aydin D, Dulgar O, Er MM, Teker F, Yavuzsen T, Aykan MB, Inal A, Iriagac Y, Kalkan NO, Keser M, Sakalar T, Menekse S, Kut E, Bilgin B, Karaoglanoglu M, Sunar V, Ozdemir O, Turhal NS, Karadurmus N, Yalcin B, Nahit Sendur MA. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncol 2023 Mar;19(10):727-736. doi: 10.2217/fon-2022-1287.

15.Oven Ustaalioglu BB, Bilici A, Seker M, Kefeli U, Aydin D, Celik S, Demir T, Erkol B Prognostic Factors for Operated Gallbladder Cancer. J Gastrointest Cancer 2019 Sep;50(3):451-457. doi: 10.1007/s12029-018-0099-y

16.Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.
Future Oncol 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.

17.Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol 2023 Jul;149(8):4141-4148. doi: 10.1007/s00432-022-04252-2

18.Dinc NS, Aydın K, Odabas H, Ercelep O, Tufan G, Seker M, Yasar N, Aydin D, Yuksel S, Mert A, Ozcelik M, Korkmaz T, Yildiz R, Aliustaoglu M, Mayadagli A, Dane F, Gumus M. Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer. Oncol Res Treat 2016;39(3):130-4. doi: 10.1159/000444272

19.Ercelep O, Topcu TO, Bayoglu IV, Ekinci AS, Koca S, Kavgaci H, Ozcelik M, Alacacioglu A, Uzunoglu S, Bozkurt O, Ulas A, Aksoy A, Taskoylu BY, Gumussay O, Yaman S, Uysal M, Aydin D, Gumus M. Retrospective multicenter evaluation of patients diagnosed with mucosal melanoma: a study of Anatolian Society of Medical Oncology. Tumour Biol

2016 Sep;37(9):12033-12038. doi: 10.1007/s13277-016-5076-0.

20.Koca S, Beşiroğlu M, Özçelik M, Karaca M, Bilici M, Hacıoğlu B, Doğu GG, Kaplan NB, Oruç Z, Aydın D, Dane F. Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study. J Oncol Pharm Pract 2021 Apr;27(3):541-546.

doi: 10.1177/1078155220924075

21.Senol S, Ceyran AB, Kösemetin D, Gobanoglu B, Aydin D, Duran EA, Leblebici M. Immunohistochemical Profile of Tumor Pathways and Prognostic Significance in Colon Adenocarcinomas. J Environ Pathol Toxicol Oncol 2017;36(1):29-41. 

doi: 10.1615/JEnvironPatholToxicolOncol.2017016530

22.Senol S, Aydin A, Kosemetin D, Ece D, Akalin I, Abuoglu H, Duran EA, Aydin D, Erkol B. Gastric Adenocarcinoma Biomarker Expression Profiles and their Prognostic Value. J Environ Pathol Toxicol Oncol 2016;35(3):207-222.

doi: 10.1615/JEnvironPatholToxicolOncol.2016016099

Read more